FDA’s Total Product Life Cycle Program Promotes Streamlined Development

CDRH’s new development initiative — Total Product Life Cycle Advisory Program (TAP) — taps into an FDA goal: to ensure U.S. patients are first to benefit from innovative medical devices that, while developed quickly, are of high quality, safe and proven effective, and that include input from patients, providers and payers early in the process.
Source: Drug Industry Daily